This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Espinoza, L. R. Articles by Seleznick, M. Search for Related Content PubMed PubMed Citation Articles by Espinoza, L. R. Articles by Seleznick, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB INDOMETHACIN Social Bookmarking                         What's this?

Refractory Nephrotic Syndrome in Lupus Nephritis: Favorable Response to Indomethacin Therapy

Sections of Rheumatology, Departments of Medicine, Louisiana State University School of Medicine at New Orleans

Luis J. Jara

Sections of Rheumatology, Departments of Medicine, Louisiana State University School of Medicine at New Orleans

Pindaro Martinez-Osuna

Sections of Rheumatology, Departments of Medicine, Louisiana State University School of Medicine at New Orleans

Luis H. Silveira

Sections of Rheumatology, Departments of Medicine, Louisiana State University School of Medicine at New Orleans

Marta Lucia Cuellar

Sections of Rheumatology, Departments of Medicine, Louisiana State University School of Medicine at New Orleans

Mitchel Seleznick

University of South Florida College of Medicine, Tampa, USA

The effects of indomethacin on urinary protein excretion, levels of serum albumin and renal function were studied prospectively in six patients with systemic lupus erythematosus (SLE) and refractory nephrotic syndrome due to lupus nephritis. Two had membranoproliferative glomerulonephritis, two had diffuse proliferative glomerulonephritis, and one each had mesangioproliferative and membranous glomerulonephritis. All experienced a considerable reduction in urinary protein excretion and an increase in serum albumin. Indomethacin was discontinued in two patients because of side effects, and proteinuria recurred to pretreatment levels. The decrease of proteinuria continued during long-term treatment in three patients. Indomethacin did not cause a permanent decline in renal function. Our results suggest that therapy with indomethacin may be beneficial for the treatment of refractory nephrotic syndrome in selected SLE patients. However, because of potential side effects the administration of indomethacin should be monitored closely.

Key Words: Lupus nephritis • Anti-inflammatory therapy • Renal insufficiency • Proteinuria • Immunosuppressive therapy

Lupus, Vol. 2, No. 1, 9-14 (1993)
DOI: 10.1177/096120339300200103


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?